Zydus Lifesciences Limited has informed the Exchange about press release dated 16-Nov-2022 titled Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast- an innovative prognostic test for breast cancer patients
Press Release Nov 16 2022
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited announced it has obtained exclusive marketing rights for CanAssist Breast, a prognostic test for breast cancer patients. This test helps determine whether hormone positive breast cancer patients require chemotherapy, potentially avoiding unnecessary treatments. CanAssist Breast is developed by OncoStem and offers a cost-effective solution compared to existing tests performed abroad. The company aims to enhance cancer care in India by providing innovative and affordable treatment options.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Nov 08 2022
- Press Release Nov 07 2022
- Press Release Nov 03 2022
- Press Release Oct 29 2022
- Press Release Oct 26 2022
Later from Zydus Lifesciences
- Press Release Nov 23 2022
- Press Release Nov 28 2022
- Press Release Dec 01 2022
- Press Release Dec 02 2022
- Press Release Dec 10 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences